Professor Mark A Stoové
Head of Public Health
Working groups
Background
Professor Stoové is head of public health at Burnet Institute where he also heads research groups in HIV prevention and justice health.
For over 20 years, Professor Stoové has undertaken research on the epidemiology and prevention of blood borne viruses and sexually transmitted infections, and the health and wellbeing of affected populations. His research focuses on generating evidence for effective public health policy and practice.
Professor Stoové has strong interests in developing novel and innovative approaches to epidemiological research to inform clinical and public health policy and practice. He has:
- led the development and maintenance of innovative sentinel surveillance systems for HIV and other sexually transmitted infections and blood borne viruses in developed and low- and middle-income countries
- led large bio-behavioural prospective cohort studies of people who inject drugs and other groups disproportionately affected by viral hepatitis, HIV and other sexually transmitted infections
- helped lead large-scale sexual health and sexually transmitted infection prevention program implementations and randomised controlled trials in Australia and low income settings internationally.
Professor Stoové has published over 320 peer reviewed papers and assumes various editorial roles for national and international technical advisory committees and international peer review journals. Over the past 10 years he has attracted AUD$90 million in research funds as a chief investigator.
Qualifications
- 2004: PhD, Victoria University, Melbourne, Australia.
- 1999: Grad Dip (Ed) RMIT, Melbourne, Australia
- 1995: BA AppSci (Hons, First Class), Victoria University, Melbourne, Australia.
Positions
- 2017: Co-Head, Eliminate HIV sub-Program, Disease Elimination Program, Burnet Institute
- 2012: Head, HIV Research; Head, Justice Health Research, Burnet Institute
- 2017: Head of Public Health Discipline, Burnet Institute
- 2011: Principal for Sexual and Reproductive Health, Burnet Institute
- 2007-2012: Senior Research Fellow / Head of HIV/STI Research - Centre for Population Health, Burnet Institute, Victoria, Australia
- 2007-present: Honorary Research Fellow - School of Psychology, Deakin University, Victoria, Australia
- 2008-present: Adjunct Research Fellow – Department of Epidemiology and Preventive Medicine, Faculty of Medicine, Nursing and Health Sciences, Monash University, Victoria, Australia
Burnet publications
View 331 moreUsing the socioecological model to guide service delivery improvements to the prison needle exchange program in Canada: insights from multi-level stakeholders
BMC Public Health
Nadine Kronfli et al
Treatment outcomes for people with hepatitis C referred to tertiary care in Victoria, 2021–22: a retrospective observational study
The Medical Journal of Australia
Elly Layton et al
The hepatitis C cascade of care for opioid agonist therapy recipients in Australia
Clinical Infectious Diseases
S. Griffin et al
Reports and other work
-
The Optimise Study: A rapid survey examining frequency, impacts of long COVID and associated concerns. (PUBLIC HEALTH REPORT)
Long COVID is estimated to be costing the Australian economy $3.6 billion annually.1 Partly because of the variation in the definition of long COVID
The Optimise Study: A rapid survey examining frequency, impacts of long COVID and associated concerns. (PUBLIC HEALTH REPORT) -
The Forest proposal
Explains how we developed The Forest - a model to address underlying causes of incarceration.
The Forest proposal -
The Forest co-design report (Burnet Institute and Paper Giant)
Describes the process and evidence behind The Forest - a model to address underlying causes of incarceration.
The Forest co-design report (Burnet Institute and Paper Giant)
-
Economic and health cost benefit impacts of The Forest (Insight Economics)
Describes the economic and social benefits of The Forest - a model to address underlying causes of incarceration.
Economic and health cost benefit impacts of The Forest (Insight Economics) -
2020: Australia’s progress towards hepatitis C elimination annual report
2020: Australia’s progress towards hepatitis C elimination annual report -
The Optimise Study:- Impacts of the COVID-19 response on culturally and linguistically diverse communities. (PUBLIC HEALTH REPORT)
The Optimise Study:- Impacts of the COVID-19 response on culturally and linguistically diverse communities. (PUBLIC HEALTH REPORT) -
COVID-19 testing and vaccination. (PUBLIC HEALTH REPORT)
COVID-19 testing and vaccination. (PUBLIC HEALTH REPORT) -
The Optimise Study: COVID-19 worry and perceptions about infection and potential severity. (PUBLiC HEALTH REPORT)
This report evaluates the impact of the COVID-19 pandemic on participants’ lives: their main concerns, risk perception, and confidence in the State and Federal Governments’ responses to the COVID-19 pandemic. This report focusses on trends over the past six months (between September 2021 and February 2022).
The Optimise Study: COVID-19 worry and perceptions about infection and potential severity. (PUBLiC HEALTH REPORT) -
2019: Australia’s progress towards hepatitis C elimination annual report
Hepatitis C poses a significant public health concern in Australia, with over 170,000 individuals estimated to be living with chronic hepatitis C infection as of the beginning of 2017. Until the availability of direct-acting antivirals (DAAs) for all Medicare-eligible Australians with hepatitis C infection on March 1st, 2016, there was a growing population of individuals living with hepatitis C. This trend was accompanied by an increasing burden of liver disease, rising rates of liver cancer, and premature deaths attributed to long-term hepatitis C infection.
2019: Australia’s progress towards hepatitis C elimination annual report
Current projects
View 16 more
We keep us safe: working with communities to end domestic, family and sexual violence
We're working with criminalised communities to help end domestic, family and sexual violence.
Supervised Injecting Room Cohort study (SIRX)
A cohort study of people who inject drugs and who use the Melbourne Supervised Injecting Rooms.
Methamphetamine and injecting drug use cohort studies: MIXMAX
MIXMAX is the largest active cohort study of people who use drugs in Australia. It combines 2 pre-existing studies: SuperMIX and VMAX.
Past projects
View 14 more
The Optimise Study: Optimising Isolation, Quarantine and Distancing for COVID-19
This project aims to find out how Victorians are experiencing COVID-19 and responding to the measures introduced to stop the spread of the virus.
WHISPER and SHOUT: mobile phone health interventions among sex workers in Kenya
We conducted a mobile phone-based health promotion with women who are sex workers in Mombasa, Kenya, to reduce unintended pregnancy.
Eliminate C (EC) Victoria partnership
A partnership aimed at increasing hepatitis C treatment uptake among people who inject drugs (PWID) using nurse-led models of care in community and prison settings.
News and features
View 4 more
Global project aiming to 'break down' hepatitis C
On World Hepatitis Day, Burnet is actively supporting this year’s theme – ‘Let’s Break It Down’ – through our partnership in a global program to develop high-quality approaches to testing and treatment.
Prison needle programs could save double what they cost – our new modelling shows how
Australia leads the world in community-based needle and syringe programs. But they are not used in Australian prisons – which are hotspots for injection-related infections.
